EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 4.0

The China Paradox in LEAP-012 Trial

Masatoshi Kudo

Liver Cancer · 18.05.2026 · 15 (3) · 329-336

DOI: 10.1159/000552537 ↗

Kurz gefasst

Editorial in der Zeitschrift Liver Cancer, online erschienen am 18.05.2026. Verfasst von Masatoshi Kudo. Beteiligte Einrichtung: Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

comparing lenvatinib plus pembrolizumab combined with TACE and dual placebo plus TACE in the global cohort and the Chinese subgroup. PFS was longer in the Chinese subgroup than in the global cohort in the combination arm, whereas the opposite pattern was observed in the dual placebo plus TACE arm, with shorter PFS in the Chinese subgroup.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaLEAP-012LenvatinibPembrolizumabTransarterial chemoembolization

Autor:innen und Institutionen

  • Editor-in-Chief, Liver Cancer, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan.

Zitieren

APA

Kudo, M. (2026). The China Paradox in LEAP-012 Trial. Liver Cancer, 15(3), 329-336. https://doi.org/10.1159/000552537

Vancouver

Kudo M. The China Paradox in LEAP-012 Trial. Liver Cancer. 2026;15(3):329-336. doi:10.1159/000552537

BibTeX
@article{Kudo2026,
  author = {Kudo, Masatoshi},
  title = {The China Paradox in LEAP-012 Trial},
  journal = {Liver Cancer},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {329--336},
  doi = {10.1159/000552537}
}
Kostenlos starten →